Fang-TaoLing. Rabies. In: Hui-LanZhong, ed. Trop Med1986: 305–313 (in Chinese).
2.
Fang-TaoLinZhenZen FanLong-MuLuThe primary hamster kidney cell rabies vaccine. Adaptation of viral strain, production of vaccine and pre- and post-exposure treatment. J Infect Dis1983;147:467–73.
3.
Wei-KangLiaoXi-KangDingXi-ShengChenJin-JingYouLian-FangTao. The diagnostic test of rabies virus in Shanghai City. J China Health1957; 5: 359 (in Chinese).
4.
Vaccine Department, Institute of Control of Biological Products, Ministry of Public Health. Methods of production of sheep brain Semple vaccine and some experimental results of products. Commun Biolog Prod1958;3:46–9 (in Chinese).
5.
Wuhan Institute of Biological Products, Ministry of Public Health. Problems of the production and control of the Semple vaccine. Commun Biolog Prod1958;3:42–6 (in Chinese).
6.
HabelK. Habel test for potency. In: KaplanMMKoprowskiH, eds. Laboratory Techniques in Rabies, 3rd edn.Geneva: World Health Organization, 1973:276–7.
7.
Yu-JunXieTaoLin FangRong-FangZenPan-SongMin-ZhiChen. Study on Freeze-dried Ether Inactivated Rabies Vaccine for Human Use: Collection of Research Achievements in 30 years 1950–1980. China: Wuhan Institute of Biological Products, Ministry of Public Health, 1982: 49 (in Chinese).
8.
WiktorTJFernandesMVKoprowskiH. Cultivation of rabies virus in human diploid cell strain WI-38. J Immunol1964;93:353–66.
9.
RappaportC. Monolayer cultures of trypsinized monkey cells in synthetic medium, application to poliovirus synthesis. Proc Soc Expl Biol Med1956;91:464–70.
10.
Fang-TaoLinXiao-ZengLuShu-BangChengFurther study on the stability and efficacy of the primary hamster kidney cell rabies vaccine. In: VodopijaI, ed. Improvements in Rabies Exposure Treatment. Zagreb: Institute of Public Health, 1985:37–45.
11.
Fang-TaoLin. The protective effect of the large-scale use of PHKC rabies vaccine in humans in China. Bull WHO1990;68:449–54.
12.
SeligmannEBJr. The NIH test for potency. In: KaplanMMKoprowskiH, eds. Laboratory Techniques in Rabies, 3rd edn.Geneva: WHO, 1973:279–86.
13.
AtanasiuP. Quantitative assay and potency test of antirabies serum and immunoglobulin. In: KaplanKoprowskiH, eds. Laboratory Techniques in Rabies, 3rd edn.Geneva: WHO, 1973:314–18.
14.
WHO. Guide for post-exposure. In: WHO Expert Committee on Rabies, 8th Report, WHO Technical Report Series 824. Geneva: WHO, 1992:55.
15.
BaltazardMBahmanyarMGhodssMSahetiAGajdusekCRouzbehiE. Essai pratique du sérum antirabique chez les mordus par loupes enragés. Bull WHO1955;13:747–72.
16.
Ministry of Public Health. Regulation of Biological Products. China: Ministry of Public Health, 1990: 110–15 (in Chinese).
17.
BögelKMotsschwillerE. Incidence of rabies and post-exposure treatment in developing countries. Bull WHO1986;64:883–7.
18.
BögelKMeslinFX. Economics of human and canine rabies elimination. Guidelines for programme orientation. Bull WHO1990;68:281–91.
19.
Guan-MuDongZeng-ShunLiuYony-QuinYoZi-LinYanJin-HuaLiu. Studies of adaptation and passage on rabies virus (CTN-1) strain in Vero cell cultures. Progr Microbiol Immunol1995;23:82–5 (in Chinese).
20.
Hong-ReiGaoZhi-DongWeiXiu-QinDanEstablishment of rabies virus strain adapted to Vero cell and study on its possibility for vaccine preparation. Prog Microbiol Immunol1995;23:129–32 (in Chinese).
21.
FengLinJia-HongZhuNai-MinChenYun-DeHouEspositoJoseph J. Construction and characteristic of vaccinia virus recombinants expressing rabies virus glycoprotein. Chinese J Virol1992;8:210–17 (in Chinese).
22.
Wei-GuoZhouTaminAgaihiJia-HongZhuJi-LinWangBinCaiEspositoJoseph J. Co-expression of rabies virus glycoprotein and nucleoprotein in vaccinia virus Tian Tan strain. Virologica Sinica1995;10:15–21 (in Chinese).